...
首页> 外文期刊>Clinical & developmental immunology. >T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers
【24h】

T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers

机译:T淋巴细胞和炎症性介体在阿尔茨海默氏病脑与血相互作用中的作用:潜在的新生物标志物库

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the main cause of dementia. The disease is among the leading medical concerns of the modern world, because only symptomatic therapies are available, and no reliable, easily accessible biomarkers exist for AD detection and monitoring. Therefore extensive research is conducted to elucidate the mechanisms of AD pathogenesis, which seems to be heterogeneous and multifactorial. Recently much attention has been given to the neuroinflammation and activation of glial cells in the AD brain. Reports also highlighted the proinflammatory role of T lymphocytes infiltrating the AD brain. However, in AD molecular and cellular alterations involving T cells and immune mediators occur not only in the brain, but also in the blood and the cerebrospinal fluid (CSF). Here we review alterations concerning T lymphocytes and related immune mediators in the AD brain, CSF, and blood and the mechanisms by which peripheral T cells cross the blood brain barrier and the blood-CSF barrier. This knowledge is relevant for better AD therapies and for identification of novel biomarkers for improved AD diagnostics in the blood and the CSF. The data will be reviewed with the special emphasis on possibilities for development of AD biomarkers.
机译:阿尔茨海默氏病(AD)是一种慢性神经退行性疾病,是痴呆症的主要原因。该疾病是现代世界最主要的医学问题之一,因为仅对症治疗可用,并且不存在用于AD检测和监测的可靠且容易获得的生物标志物。因此,进行了广泛的研究以阐明AD发病机制,其似乎是异质的和多因素的。最近,注意力已经集中在AD脑中神经炎症和神经胶质细胞的活化上。报道还强调了T淋巴细胞浸润AD脑的促炎作用。然而,在AD中,涉及T细胞和免疫介质的分子和细胞改变不仅在大脑中发生,而且在血液和脑脊液(CSF)中发生。在这里,我们回顾了有关AD大脑,CSF和血液中T淋巴细胞和相关免疫介质的变化以及外周T细胞穿过血脑屏障和血液CSF屏障的机制。该知识与更好的AD治疗以及鉴定新的生物标记物有关,以改善血液和CSF中的AD诊断。将对数据进行审查,并特别强调开发AD生物标志物的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号